Centrient Pharmaceuticals, a specialist in statins and anti-fungals, has started production at its second dedicated statins manufacturing unit at its Toansa, India site. With the building now completed, the company will double its statins production capacity, enabling the company to meet demand for its sustainably manufactured Atorvastatin and Rosuvastatin APIs.
The markets for Atorvastatin and Rosuvastatin have shown steady growth in the past years, resulting from the continued global prevalence of high cholesterol issues, replacement of older generation statins, and genericisation of the market.
Centrient says it’s able to offer security of supply to customers through its dedicated statins production facility and backward integration, meaning it’s independent from external imports of starting materials. The company claims its enzymatic route of synthesis and patented technology minimise the use of harmful solvents, generate less waste, and reduces its carbon footprint.
“With the doubling of our production capacity, we demonstrate our commitment to maintain our leadership position in line with our strategy and to continue supporting our customers’ business growth,” said Frans Vlaar, CCO at Centrient.
Ground breaking of the manufacturing unit started at the end of 2019 and commercial supplies from the unit will start in mid-2021. With the manufacturing line being operational and doubling the production capacity, the company will be better positioned to secure supply, meeting demand from customers and helping to improve the lives of patients who are in need of these medicine.
“We are extremely proud that we have been able to complete this project in a timely way given the challenges of executing such a complex project in the midst of the COVID pandemic,” said Jim McPherson, Chief Quality & Technical Operations Officer. “It reinforces our absolute commitment to meet the expectations of our customers as a partner of choice - delivering reliable and secure supply using leading sustainable technologies. The facility incorporates design features that allow further improvements in GMP and energy utilisation and enable greater automation for improved process control.”
